Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 2, 2012, Pages 158-164

  Morgan, Roger E ^a   Campbell, Stuart E ^a   Suehira, Kazuhito ^a,b   Sponseller, Craig A ^b   Yu, Christine Y ^c   Medlock, Matthew M ^d  

^a Kowa Research Institute Inc   (United States)

^b Kowa Pharmaceuticals America Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Pharmaceutical Product Development   (United States)

Author keywords

Drug drug interaction; HMG CoA; Lopinavir; Pitavastatin; Ritonavir

Indexed keywords

LOPINAVIR; PITAVASTATIN; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG INTERACTIONS; FEMALE; HUMAN EXPERIMENTATION; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LOPINAVIR; MALE; MIDDLE AGED; QUINOLINES; RITONAVIR; UNITED STATES; YOUNG ADULT;

EID: 84862136276     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318251addb     Document Type: Article

References (21)

1. Calza L, Manfredi R, Pocaterra D, et al. Risk of premature atherosclerosis cand ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect. 2008;57:16-32.
2. Fujino H, Saito T, Tsunenari Y, et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica. 2004; 34:961-971. (Pubitemid 40070099)
3. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577. (Pubitemid 34218852)
4. Masana L. Pitavastatin-from clinical trials to clinical practice. Atheroscler Suppl. 2010;11:15-22.
5. Betteridge J. Pitavastatin-results from phase III & IV. Atheroscler Suppl. 2010;11:8-14.
6. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33:27-41. (Pubitemid 36071761)
7. Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag. 2009;5:921-936.
8. Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139-146. (Pubitemid 39287793)
9. Hirano M, Maeda K, Shitara Y, et al. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34:1229-1236.
10. Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res. 2004;21: 1622-1630; Springer Netherlands. (Pubitemid 41184393)
11. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996;277:423-431. (Pubitemid 27169089)
12. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693-705.
13. Kaletra (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: Abbott Laboratories; [revised February 2011]. Cited March 15, 2011.
14. Tungsiripat M, Aberg JA. Dyslipidemia in HIV patients. Cleve Clin J Med. 2005;72:1113-1120.
15. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drugdrug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin [abstract 55]. Presented at: 8th International Workshop on Pharmacology of HIV Therapy; April 16-18, 2007; Budapest, Hungary. 2007.
16. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-578. (Pubitemid 351442013)
17. van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12:1127-1132. (Pubitemid 350114993)
18. Bonnet F, Aurillac-Lavignolle V, Breilh D, et al. Pravastatin in HIVinfected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials. 2007;8:53-60. (Pubitemid 46542908)
19. Montes ML, Pulido F, Barros C, et al. Lipid disorders in antiretroviralnaive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother. 2005;55: 800-804. (Pubitemid 40691867)
20. Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am. 2009; 38:207-222.
21. NIH Clinical Trials Registry. A 12-week study comparing pitavastatin 4 mg vs. pravastatin 40 mg in HIV-infected subjects. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01301066?term=pitavastatin&recr= Open&rank=9.